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Abstract 
Purpose: To develop a first-order derivative spectrophotometric method for the determination of 
trimethoprim (TMP) and sulfamethoxazole (SMX) from fixed-dose combination generic products using a 
flow-through cell technique.  
Methods: Absorbance measurement was achieved at 247.8 and 257.9 nm for trimethoprim and 
sulfamethoxazole, respectively. USP Apparatus 4 with 22.6 mm cells, laminar flow at 16 ml/min, and 0.1 
N HCl at 37 °C as dissolution medium, were used. Dissolution profiles were compared with model-
dependent and independent methods. 
Results: All the products met the pharmacopeial dissolution criterion (Q ≥ 70 %, at 60 min), except 
SMX in two products (SC 400 mg and SB1 800 mg) using the flow-through cell (53.62 and 49.74 % 
dissolved, respectively). Using both USP apparatuses, significant differences in mean dissolution time 
and dissolution efficiency values were found (p < 0.05). All products were in line with Weibull’s kinetics 
and significant differences in derived parameters (Td) values were found (p < 0.05). 
Conclusion: Determination of TMP and SMX by derivative spectrophotometry can easily be employed 
for dissolution studies using the flow-through cell technique. However, it would be necessary to 
determine correlation with in-vivo test results in order to assure safe interchangeability. 
 
Keywords: Trimethoprim, Sulfamethoxazole, Flow-through cell method, First-order derivative 
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Recently, several authors have been worried 
about safe interchangeability between branded 
products and its generic counterpart or even 
among different generic products. For several 
drugs, interesting and different results have been 
reported [1,2]. Importance of in-vitro dissolution 
test to guarantee a best quality in generic 
medications is widely discussed by regulatory 
organisms [3]. According to FDA and WHO 
guidelines, some generic drugs can be registered 
on the basis of only in-vitro data (dissolution test) 
without testing their in-vivo performance [4]. In 
Mexico, as in other parts of the world, 
trimethoprim-sulfamethoxazol (TMP-SMX) imme-
diate-release oral fixed-dosage forms are 
marketed as generic drugs. The combination is 
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prepared in different formulations but tablets are 
the most commonly used, mainly for the 
advantages of patient management and intake of 
a solid dosage form. 
 
TMP-SMX inhibits bacterial synthesis of 
tetrahydrofolic acid, the physiologically active 
form of folic acid and a necessary cofactor in the 
synthesis of thymidine, purines and bacterial 
DNA. The fixed 1:5 formulation of TMP-SMX is 
indicated primarily for treating genitourinary, 
gastrointestinal, and respiratory tract infections 
as well as skin-associated infections and HIV-
infected patients [5]. Development of bacterial 
resistance and adverse reactions are well 
documented [6]. 
 
According to Biopharmaceutical Classification 
System, TMP and SMX are classified as Class II 
drugs [7]. Due to their low aqueous solubility, 
dissolution rate is the rate-limiting step for 
absorption. TMP and SMX are well absorbed 
after oral administration however; TMP is 
absorbed more rapidly than SMX and is more 
widely distributed throughout the body. Because 
of this unequal distribution, a widely range of 
concentrations is achieved in different tissues 
and body fluids [6]. Furthermore, in-vitro 
dissolution data offer the best method to predict 
in-vivo performance formulation. In this regard, 
some authors have been documented 
differences in in-vitro release characteristics of 
TMP-SMX commercial products [8]. 
 
Spectrophotometric approaches for simultaneous 
analysis of binary and ternary mixtures in 
commercial tablets were previously reported 
[9,10]. Studies are often focused on in-vitro 
dissolution profiles of TMP-SMX without previous 
extraction steps and interference of matrix effect; 
however, alkaline or a combination of 
alkaline/methanolic solutions are usually used in 
those studies but pharmacopeial dissolution 
method is carried out in acidic medium (0.1 N 
HCl). Other kinds of solutions are not the natural 
environment where drugs will be dissolved within 
the first minutes after tablets intake. Dissolution 
profiles of TMP-SMX commercial products with 
derivative spectrophotometry were also reported. 
The aid of some devices and continuous-flow 
methodology knowing as multi-commutation is 
included [11]. For pharmaceutical analysis of 
TMP-SMX brand products, automated dissolution 
systems fitted with an integrated multicomponent 
detector was reported [8]. Determination of 
multicomponent dissolution profiles of TMP-SMX 
pharmaceutical products by in-situ fiber-optic UV 
measurements was also described [12]. For 
current pharmaceutical laboratories these 
equipments are not easily available and routine 
dissolution profiles comparisons with binary 
mixtures is difficult to carry out. 
 
For the evaluation of dissolution profiles of TMP-
SMX tablets, the United States Pharmacopeia 
(USP) [13] specifies the use of USP paddle 
method at 75 rpm with 900 ml of 0.1 N HCl as 
dissolution medium and not less than 70 % (Q) of 
TMP-SMX is dissolved in 60 min. HPLC analysis 
for drugs quantification is recommended. An 
alternative to evaluate in-vitro drug release is the 
flow-through cell system (USP Apparatus 4). Its 
advantages over the conventional basket and 
paddle methods (USP Apparatus 1 and 2, 
respectively) are widely demonstrated, especially 
for the dissolution of poorly soluble drugs [14,15]. 
The USP Apparatus 4 best simulates the 
hydrodynamic conditions that are found in the 
gastrointestinal tract. Therefore, it is important to 
investigate the applicability of the flow-through 
cell system on the assessment of TMP-SMX 
dissolution profiles in order to ensure the 
adequate biopharmaceutical evaluation of fixed-
dose combination generic drugs. 
 
The aim of this study was to apply a first-order 
derivative spectrophotometric method, especially 
developed for dissolution studies (USP paddle 
method), in the determination of dissolution 
profiles of TMP and SMX from fixed-dose 
combination generic drugs obtained with the 
flow-through cell system. Results were compared 
with data obtained with the pharmacopeial 




Products and standard solutions 
 
Seven TMP-SMX immediate-release commercial 
products were used. Different letter was 
assigned to each one (A, B and C for 80 mg of 
TMP and 400 mg of SMX tablets) and (A1 and 
B1 for 160 mg of TMP and 800 mg of SMX 
tablets). Dissolution profiles of generic drugs 
were compared to dissolution profiles of the 
Mexican reference products (R and R1) 
Bactrim® and Bactrim® F (Productos Roche, SA 
de CV, Mexico). Hydrochloric acid and methanol 
analytical grade were purchased from JT Baker-
Mexico. TMP and SMX standards were 
purchased from Sigma-Aldrich Co. (St. Louis 
MO, USA). All samples were filtered through 0.45 
µm nitrocellulose filters (Millipore®, Ireland). 
 
Standard solutions of both drugs were separately 
prepared by serial dilutions of the stock solutions 
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of TMP (0.2 mg/ml) and SMX (1 mg/ml) in 0.1 N 
HCl to achieve the concentrations of 10–50 
µg/ml of TMP and 250–350 µg/ml of SMX in the 
same medium. 
 
Content uniformity and assay 
 
Content uniformity and assay tests were 
performed with all products, according the 
procedures described in the USP [13]. 
 
Analytical method validation 
 
The proposed analytical method was validated 
according to the International Conference on 
Harmonization (ICH) guidelines [16]. The system 
linearity, accuracy and precision were analyzed. 
 
Pharmacopeial dissolution method (USP 
Apparatus 2) 
 
TMP-SMX dissolution profiles were carried out 
according the procedures described in the USP 
[13]. An USP paddle apparatus (Sotax AT-7 
Smart, Switzerland) with a piston pump (Sotax 
CY7-50, Switzerland) was used. Tablets were 
added on 900 ml of 0.1 N HCl at 37.0 ± 0.5 ºC (n 
= 6). Rotational speed of 75 rpm was tested. 10 
ml of filtered samples were withdrawn at 15, 20, 
30, 45, and 60 min and replaced with an equal 
volume of fresh dissolution medium to maintain a 
constant total volume. 
 
Flow-through cell method (USP Apparatus 4) 
 
TMP-SMX dissolution profiles were obtained with 
an automated flow-through cell system, USP 
Apparatus 4 (Sotax CE6, Sotax AG, Switzerland) 
with 22.6 mm cells (i.d.) and a piston pump 
(Sotax CY7−50, Sotax AG, Switzerland). In all 
experiments, laminar flow (with a bed of 6 g of 
glass beads) at 37.0 ± 0.5 °C was used. The 
degassed 0.1 N HCl was used as the dissolution 
medium, at a flow rate of 16 ml/min and an open 
system was used. Dissolution samples were 
taken at 15, 20, 30, 45 and 60 min (n = 6). 
 
First-order derivative spectrophotometric 
analysis 
 
Simultaneous determination of TMP-SMX was 
carried out with a first-order derivative 
spectroscopic method previously developed in 
our laboratory [17]. A double beam UV/Vis 
spectrophotometer (Perkin Elmer Lambda 35, 
Waltham MA, USA) with 0.1 cm quartz cells was 
utilized. The operating conditions for UV analysis 
were first-derivative mode with scan speed 240 
nm/min, slit width 2.0 nm, and sampling interval 
1.0 nm. The amounts of TMP-SMX dissolved in 
both dissolution apparatuses were determined at 
247.8 and 257.9 nm respectively, with reference 




TMP-SMX dissolution data of each product were 
used to calculate model-independent 
parameters: % dissolved at 60 min (Q), mean 
dissolution time (MDT) [18] and dissolution 
efficiency (DE) [19]. The values of these 
parameters from generic drugs were compared 
with the reference products values by ANOVA 
followed by Dunnett’s or Dunnett’s T3 multiple 
comparisons test as appropriate. Data analysis 
was carried out using SPSS software (Version 
17.0). Differences were considered significant if p 
< 0.05. 
 
Additionally, in order to evaluate the release 
kinetics of TMP and SMX from the used 
products, dissolution data were fitted to different 
kinetic models: First order, Higuchi, Korsmeyer-
Peppas, Hixson-Crowell, Weibull and Logistic. 
The model with highest determination coefficient 
(R2adjusted) and minimum Akaike Information 
Criterion (AIC) was chosen as the best fit [20]. 
Data analysis was carried out using Excel add-in 
DDSolver program [21]. To compare dissolution 
profiles with model-dependent methods a 
parameter derived from the best fit model was 
compared with an univariate one-way ANOVA 
followed by Dunnett’s or Dunnett’s T3 multiple 
comparisons test. Differences were considered 






All products met the content uniformity and assay 
tests specified in the USP. The percentages of 
TMP-SMX on the content uniformity test ranged 
from 85–115 % and the assay test was between 
90 and 110 %, Table 1. 
 
Analytical method validation 
 
The mean regression equation from three 
standard calibration curves was y = 0.0349x + 
0.0124 for TMP and y = –0.0100x + 0.2756 for 
SMX. The relative standard deviation (RSD) 
values of response factor were 2.08 and 1.79 % 
for TMP and SMX ranges, respectively. 
Considering dissolution of 80, 100 and 120 % of 
dose, the  regression  equation  to assess  the 
method linearity was y = 1.0005x – 0.0227 for 
TMP and y = 1.0013x + 0.4559 for SMX (R2 = 
0.998; p < 0.05).  The  method  accuracy  was 
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Table 1: Mean content uniformity and assay results of trimethoprim (TMP) and sulfamethoxazole (SMX); n = 10 
 






TR 80 99.17-101.03 100.09 
TA 80 102.59-104.89 103.77 
TB 80 103.50-106.24 104.68 
TC 80 100.72-103.22 102.21 
SMX 
SR 400 103.68-105.62 104.65 
SA 400 98.38-100.58 99.51 
SB 400 99.01-101.63 100.13 
SC 400 101.97-104.50 103.48 
TMP 
TR1 160 100.84-103.00 101.88 
TA1 160 99.06-100.44 99.95 
TB1 160 101.48-103.83 102.61 
SMX 
SR1 800 97.48-99.56 98.48 
SA1 800 99.70-101.09 100.59 
SB1 800 101.84-104.20 102.98 
 
99.94 % for TMP and 100.27 % for SMX. The 
higher RSD value calculated to assess the 
method precision was 1.59 %. All commercial 




TMP-SMX dissolution profiles obtained with the 
flow-through cell system and the USP paddle 
method are shown in Figure 1. Considering a 
single point specification (Q ≥ 70 % in 60 min) all 
products met the pharmacopeial dissolution 
criterion in both USP apparatuses, excepting 
SMX in products SB (400 mg) and SB1 (800 mg) 
using USP Apparatus 4 (53.62 and 49.74 % 
dissolved, respectively). TMP-SMX dissolution 
test using the USP paddle method did not 
differentiate between the dissolution profiles; 
based on the pharmacopeial specifications all 




MDT and DE mean values ± standard error for 
products under study in both USP apparatuses 
are shown in Table 2. Considering model-
independent comparisons significant differences 





In order to describe the TMP-SMX release 
kinetics from generic drugs, data were fitted to 
several kinetics models. Low values of R2adjusted 
and high values of AIC were found with almost all 
models. The dissolution data of all products in 
the flow-through cell system and the USP paddle 
method were best fitted by Weibull’s function and 
the comparison of dissolution profiles was made 
analyzing the derived parameter (Td) from this 
function. Significant differences in Td values 
between generic drugs and the reference 
products were found (p < 0.05) in both USP 




First-derivative spectroscopic method was 
successfully applied for TMP-SMX determination 
together with the flow-through cell apparatus. In 
USP Apparatus 2 the UV analysis is also 
adequate because in both apparatuses, TMP 
and SMX achieved an extent of dissolution of 
100 ± 3 % at 60 min from the reference products. 
In all sampling times the RSD was lower than 3 
%. Results in USP Apparatus 4 showed a slower 
dissolution rate than the one found with the USP 
paddle method. This behavior can be explained 
by the hydrodynamic conditions that characterize 
the flow-through cell, where no agitation 
mechanisms exists and the dosage form and the 
drug particles are continuously exposed to a 
uniform laminar flow, similar to the natural 
environment of the gastrointestinal tract, causing 
different in-vitro dissolution pattern [22]. In-
vitro/in-vivo correlation (IVIVC) using the flow-
through cell at flow rates of 8, 16 and 32 ml/min 
has been previously discussed [23] as well as 
flow rates of 4, 8 and 16 ml/min are also in the 
European Pharmacopeia and the USP. 
 
The analytical method validation was done with 
all products used in the present study however, 
as an example and in order that method 
validation is not the main objective of this work, 
only the reference product R (80/400 mg-dose) 
data are shown. 
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Figure 1: Dissolution profiles of trimethoprim-sulfamethoxazole from fixed-dose combination reference and 
generic products (Key: A) ● TR, ∆ TA, ○ TB and □ TC. B) ● SR, ∆ SA, ○ SB and □ SC. C) ● TR1, ∆ TA1 and ○ 
TB1. D) ● SR1, ∆ SA1 and ○ SB1) evaluated with the USP paddle method and the flow-through cell system. 
Mean, n = 6. Error bars were omitted for clarity 
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Table 2: Model-independent parameters: percentage dissolved at 60 min, mean dissolution time (MDT), and 
dissolution efficiency (DE) of trimethoprim (TMP) and sulfamethoxazole (SMX) from fixed-dose combination 
generic drugs. Data are mean ± SEM, n = 6: *p < 0.05 
 
Drug Code Dose (mg) 
% Diss. 





USP Paddle method 
TMP 
TR 80 99.28±0.45 10.55±0.14 81.81±0.21 
TA 80 94.24±0.58* 8.92±0.23* 80.22±0.44 
TB 80 83.13±0.96* 17.78±0.78* 58.53±1.56* 
TC 80 90.53±0.73* 10.33±0.33 74.94±0.77* 
SMX 
SR 400 98.63±0.26 11.79±0.18 79.25±0.18 
SA 400 98.95±0.15 10.65±0.13* 81.39±0.21* 
SB 400 72.59±2.38* 19.93±0.41* 48.46±1.54* 
SC 400 100.44±0.46* 11.22±0.18 81.65±0.27* 
TMP 
TR1 160 99.74±0.23 9.47±0.10 83.99±0.12 
TA1 160 93.39±1.73* 11.92±0.71* 74.84±1.80* 
TB1 160 80.50±0.33* 10.10±0.17 66.94±0.14* 
SMX 
SR1 800 102.77±0.39 10.07±0.17 85.52±0.14 
SA1 800 96.87±0.46* 9.83±0.22 81.00±0.23* 
SB1 800 85.81±0.20* 15.92±0.12* 63.04±0.12* 
Flow-through cell method 
TMP 
TR 80 100.96±0.48 11.43±0.24 81.72±0.40 
TA 80 99.95±1.01 13.50±0.17* 77.46±0.58* 
TB 80 77.23±1.29* 19.12±0.58* 52.59±0.72* 
TC 80 98.31±0.64 10.06±0.10* 81.82±0.42 
SMX 
SR 400 101.36±0.39 13.76±0.19 78.12±0.59 
SA 400 85.90±0.90* 15.67±0.37* 63.44±0.22* 
SB 400 53.62±0.22* 20.40±0.10* 35.39±0.10* 
SC 400 101.22±0.42 13.03±0.08* 79.24±0.37 
TMP 
TR1 160 100.88±0.52 9.71±0.19 84.54±0.20 
TA1 160 99.13±0.39 12.77±0.17* 78.02±0.17* 
TB1 160 83.47±0.74 * 9.93±0.16 69.65±0.59* 
SMX 
SR1 800 100.59±0.41 14.89±0.09 75.64±0.38 
SA1 800 95.51±0.28* 11.65±0.23* 76.96±0.46 
SB1 800 49.74±0.20* 22.38±0.02* 31.19±0.12* 
 
Results of the present study agree with those 
found by other authors where TMP from 
commercial tablets dissolved rapidly while SMX 
dissolved slowly [12,24]. For the study, USP 
Apparatus 2 at 75 rpm was used. In another 
work, considering TMP-SMX generic drugs 
comparisons, dissolution profile of SMX from a 
commercially available product was slower than 
SMX profiles of other two evaluated products [8]. 
Authors used USP paddle method and 50 rpm as 
agitation rate. 
 
In order to compare the in-vitro dissolution data 
of TMP and SMX from fixed-dose combination 
generic drugs, model-independent parameters 
MDT and DE were calculated. These parameters 
have been proposed as adequate parameters for 
some IVIVC levels [25]. IVIVC Level B 
represents a relationship between MDT and the 
mean residence time, both calculated by 
statistical moments theory. IVIVC of oral TMP-
SMX formulations using data derived from 
statistical moments analysis was previously 
reported [26]. Three formulations gave R2 of 
0.99885 including both drugs in the same 
analysis. One of them was a commercially 
available product. On the other hand, Level C 
represents a single point correlation between one 
dissolution time point (t50%, t90%, etc.) to one 
pharmacokinetic parameter such as AUC, Cmax 
or Tmax. DE was taken by some authors as a 
suitable parameter that expresses global drug 
dissolution performance useful for comparison of 
in-vitro dissolution profiles [19]. 
 
Comparison of dissolution profiles using model-
dependent methods is a common methodology. 
Several authors reported adjustments of TMP-
SMX dissolution profiles of commercially 
available formulations (tablets) to Higuchi’s 
kinetic model. They suggested that Higuchi’s 
equation  allows  an  easy  comparison  of  the 
parameters and curves and it fits better than 
polynomial equations [11]. However, results 
obtained in the present work adjusted to 
Weibull’s kinetic model. This model has proven 
to be useful to describe in-vitro release kinetics 
of poorly soluble drugs in immediate-release oral 
dosage forms [14,15]. 
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Table 3: Model-dependent parameters: α, β and Td values derived from the trimethoprim (TMP) and 
sulfamethoxazole (SMX) data adjusted to Weibull’s kinetic model. Data are mean ± SEM, n = 6: *p < 0.05 
 
Drug Code Dose (mg) α β 
Td 
(± SEM) 
USP Paddle method 
TMP 
TR 80 21.16 1.19 9.14±0.48 
TA 80 79.07 82.77 5.57±1.19* 
TB 80 1987.27 1.90 17.92±0.64* 
TC 80 84.95 84.83 5.66±0.60* 
SMX 
SR 400 8.76 0.92 9.24±0.59 
SA 400 4.13 0.67 5.66±0.90* 
SB 400 44.48 1.15 24.83±1.86* 
SC 400 55.31 1.28 9.81±0.70 
TMP 
TR1 160 132.06 1.87 10.15±0.47 
TA1 160 423.84 34.22 8.02±0.85 
TB1 160 1036.11 43.36 2.95±0.83* 
SMX 
SR1 800 66.86 1.51 9.38±0.79 
SA1 800 4979.41 2.17 10.04±0.92 
SB1 800 126.62 7.79 19.73±2.03* 
 
Flow-through cell method 
TMP 
TR 80 4.35 0.68 7.51±0.36 
TA 80 3319.53 2.88 15.67±0.11* 
TB 80 9.59 0.71 24.20±1.84* 
TC 80 1.17 0.25 1.91±0.18* 
SMX 
SR 400 9.25 0.87 12.43±0.25 
SA 400 1661.94 1.78 17.33±1.67 
SB 400 5870.83 1.71 82.50±0.62* 
SC 400 22.75 1.19 13.28±0.13 
TMP 
TR1 160 3.73 0.57 3.66±1.16 
TA1 160 3058.52 2.89 14.22±0.07* 
TB1 160 146.75 1.73 9.70±1.57* 
SMX 
SR1 800 1514.87 1.26 14.49±0.16 
SA1 800 1512.08 1.10 9.86±0.73* 
SB1 800 1967.28 1.55 86.22±0.54* 
 
The interchangeability of generic drugs is 
understood to mean the possibility for their 
mutual replacement in clinical practice while 
maintaining pharmacological response unaltered. 
The assessment of generics drugs 
interchangeability by in-vitro studies is one of the 
important task of the International 
Pharmaceutical Federation represented by the 
publication of “biowaiver monographs” [27]. 
Moreover, and with reference in the experience 
of a few countries, the role of generic medicines 
in healthcare systems and the need to establish 
and implement generic medicines policies is 
widely discussed by some authors [28]. Suitable 
in-vitro dissolution studies help to maintain an 
adequate quality control in formulations that may 






First-order derivative spectroscopy is a useful 
technique for the simultaneous determination of 
TMP and SMX dissolution profiles from fixed-
dose combination generic drugs using the flow-
through cell method. The USP Apparatus 4 is 
effective in discriminating in-vitro dissolution 
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